BlackfinBio Limited has received approval from the FDA to trial a novel therapy for Hereditary Spastic Paraplegia ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data ...

Q2 2025 Management View CEO Mitchell Steiner emphasized Veru’s focus on its obesity program, highlighting the positive Phase 2b clinical trial results for enobosarm. This drug, when combined with ...

Q1 2025 Earnings Call Transcript May 7, 2025 EyePoint Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.65 EPS, expectations were $-0.65. Operator: Good morning. My ...

TScan Therapeutics, Inc.’s TCRX share price has surged by 5.15%, which has investors questioning if this is right time to ...

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

BeyondSpring Inc.’s BYSI share price has dipped by 8.91%, which has investors questioning if this is right time to buy.

The average number of industry-funded trials started per month was 135.8 before the IRA was passed and 83.6 after — a 38.4% decrease.

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

Dosing our first patient in the VAN-2401 phase 1 trial is an important milestone in the advancement of KH658 by exploring the ...